Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

20183,700 citationsJournal Articlebronze Open Access

Authors

Mark A. Socinski · Florida Hospital Cancer Institute

Robert M. Jotte · Texas Oncology

Federico Cappuzzo · Azienda Unità Sanitaria Locale Della Romagna

Francesco Orlandi · Instituto Nacional del Tórax

Daniil Stroyakovskiy · Moscow City Oncology Hospital №62

Naoyuki Nogami · Shikoku Cancer Center

Delvys Rodríguez‐Abreu

Abstract

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status. (Funded by F. Hoffmann-La Roche/Genentech; IMpower150 ClinicalTrials.gov number, NCT02366143 .).

Topics & Keywords

Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 378, Issue 24, pp. 2288-2301

DOI: 10.1056/nejmoa1716948

Field-Weighted Citation Impact: 168.18